Novavax's two-dose COVID-19 vaccine showed 90% overall vaccine efficacy (VE), 100% protection against moderate and severe illness, and 93% VE against variants of concern and of interest in a phase 3 US clinical trial in adults, according to a company news release today.Maryland-based Novavax plans to file for regulatory authorization for adults within the next few months, the release said.
While authorization wouldn't likely have much effect on the already robust US vaccine supply, it could provide a badly needed boost to the international vaccine rollout.
Another plus is that it doesn't require ultra-cold temperatures for shipping and storage.The Coalition for Epidemic Preparedness Innovations (CEPI), a global group of government and